<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01457703</url>
  </required_header>
  <id_info>
    <org_study_id>09-0977</org_study_id>
    <secondary_id>U54HD058155</secondary_id>
    <nct_id>NCT01457703</nct_id>
  </id_info>
  <brief_title>Reproductive Hormonal Alterations in Obesity</brief_title>
  <official_title>Reproductive Hormonal Alterations in Obesity, AIMS #1 &amp; #2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine why obese women have lower hormone levels and less
      fertility than women of normal body weight. The proposal will examine the reproductive system
      at the level of the brain and the ovary to define the changes that happen leading to lowered
      hormone production. Women will be studied throughout a menstrual cycle and given medications
      that will test how well their pituitary gland can make hormones that stimulate the ovary
      (luteinizing hormone (LH) and follicle stimulating hormone (FSH)). They will also be given a
      medication to abolish estrogen production in the body and their response to this medication
      will be assessed. Finally, the ovary's ability to produce progesterone after ovulation will
      be examined.

      --Hypotheses:

        1. Obese women have reduced pituitary sensitivity to exogenous gonadotropin-releasing
           hormone (GnRH), but normal clearance of exogenous LH. (comparative study of obese
           compared to normal weight women)

        2. Obese women have abnormally increased sensitivity to estradiol negative feedback which
           will be reversed by an aromatase inhibitor. (comparative study of obese compared to
           normal weight women)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AIM 1: test the hypothesis that reduced pituitary sensitivity to GnRH-induced LH and FSH
      secretion causes the relative hypogonadotropic hypogonadism of obesity AIM 2: test the
      hypothesis that the hypothalamic-pituitary axis is abnormally sensitive to estradiol negative
      feedback in obesity
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Luteinizing Hormone (LH) Pulse Amplitude (Aim 1)</measure>
    <time_frame>Measured hourly and averaged over the 12 hour study visit</time_frame>
    <description>Luteinizing Hormone (LH) Pulse Amplitude was measured hourly during the 12 hour study visit, and was compared between the obese and normal weight groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Luteinizing Hormone (LH) Pulse Amplitude (Aim 2)</measure>
    <time_frame>Measured hourly and averaged over the 12 hour study visit</time_frame>
    <description>Luteinizing Hormone (LH) Pulse Amplitude was measured hourly during the 12 hour study visit, and was compared between the obese and normal weight groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Pregnanediol Glucuronide (PdG) (Aim 2)</measure>
    <time_frame>Averaged over the length of menstrual cycle</time_frame>
    <description>Pregnanediol glucuronide (PdG) was collected daily over the course of one menstrual cycle and averaged.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Follicle Stimulating Hormone (FSH) (Aim 1)</measure>
    <time_frame>Measured hourly and averaged over the 12 hour study visit</time_frame>
    <description>Follicle-stimulating hormone was measured hourly during the 12 hour study visit, and was compared between the obese and normal weight groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Follicle Stimulating Hormone (FSH) (Aim 2)</measure>
    <time_frame>Measured hourly and averaged over the 12 hour study visit</time_frame>
    <description>Follicle-stimulating hormone was measured hourly during the 12 hour study visit, and was compared between the obese and normal weight groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>BMI ≥30 kg/m2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2:
BMI ≥30 kg/m2
History of regular menstrual cycles every 25-40 days
Gonadorelin-GnRH (Lutrepulse), GnRH antagonists - Cetrorelix (Cetrotide), Recombinant LH (Luveris) were administered in Aim 1. GnRH or gonadorelin (Lutrepulse) and Letrozole were administered in Aim 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMI 18-25 kg/m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMI 18-25 kg/m2
History of regular menstrual cycles every 25-35 days
Gonadorelin-GnRH (Lutrepulse), GnRH antagonists - Cetrorelix (Cetrotide), Recombinant LH (Luveris) were administered in Aim 1. GnRH or gonadorelin (Lutrepulse) and Letrozole were administered in Aim 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetrorelix</intervention_name>
    <description>Abolishes pituitary sensitivity to GnRH.</description>
    <arm_group_label>BMI ≥30 kg/m2</arm_group_label>
    <arm_group_label>BMI 18-25 kg/m2</arm_group_label>
    <other_name>Cetrotide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gonadorelin-GnRH</intervention_name>
    <description>GnRH is used to stimulate the pituitary gland to produce LH and FSH.</description>
    <arm_group_label>BMI ≥30 kg/m2</arm_group_label>
    <arm_group_label>BMI 18-25 kg/m2</arm_group_label>
    <other_name>Lutrepulse</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant LH</intervention_name>
    <description>Used to stimulate ovarian function in women.</description>
    <arm_group_label>BMI ≥30 kg/m2</arm_group_label>
    <arm_group_label>BMI 18-25 kg/m2</arm_group_label>
    <other_name>Luveris</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>An aromatase inhibitor.</description>
    <arm_group_label>BMI ≥30 kg/m2</arm_group_label>
    <arm_group_label>BMI 18-25 kg/m2</arm_group_label>
    <other_name>Femara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18-40 at study entry

          -  BMI either 18-25 kg/m2 or ≥30 kg/m2

          -  prolactin (PRL) and thyroid-stimulating hormone (TSH) within normal laboratory ranges
             at screening

          -  Baseline hemoglobin &gt;11 gm/dl

          -  History of regular menstrual cycles every 25-35 days if BMI 18-25 kg/m2

          -  History of regular menstrual cycles every 25-40 days if BMI ≥30 kg/m2

        Exclusion Criteria:

          -  History of chronic disease affecting hormone production, metabolism or clearance

          -  Use of medications that are known to alter or interact with reproductive hormones
             (e.g., thiazolidinediones, metformin)

          -  Use of hormones within three months of enrollment

          -  Excessive exercise (&gt;4 hours per week)

          -  Pregnancy, breast-feeding or current active attempts to conceive
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nanette Santoro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Translational Research Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cudoctors.com/find-a-doctor/profile/?providerID=3067&amp;name=santoro</url>
    <description>PI Biographical data</description>
  </link>
  <reference>
    <citation>Jain A, Polotsky AJ, Rochester D, Berga SL, Loucks T, Zeitlian G, Gibbs K, Polotsky HN, Feng S, Isaac B, Santoro N. Pulsatile luteinizing hormone amplitude and progesterone metabolite excretion are reduced in obese women. J Clin Endocrinol Metab. 2007 Jul;92(7):2468-73. Epub 2007 Apr 17.</citation>
    <PMID>17440019</PMID>
  </reference>
  <reference>
    <citation>Haynes G, Bailey MK, Davis S, Mahaffey JE. Use of methylprednisolone in epidural analgesia. Arch Neurol. 1989 Nov;46(11):1167-8.</citation>
    <PMID>2818247</PMID>
  </reference>
  <reference>
    <citation>Rochester D, Jain A, Polotsky AJ, Polotsky H, Gibbs K, Isaac B, Zeitlian G, Hickmon C, Feng S, Santoro N. Partial recovery of luteal function after bariatric surgery in obese women. Fertil Steril. 2009 Oct;92(4):1410-5. doi: 10.1016/j.fertnstert.2008.08.025. Epub 2008 Sep 30.</citation>
    <PMID>18829008</PMID>
  </reference>
  <reference>
    <citation>Santen RJ, Bardin CW. Episodic luteinizing hormone secretion in man. Pulse analysis, clinical interpretation, physiologic mechanisms. J Clin Invest. 1973 Oct;52(10):2617-28.</citation>
    <PMID>4729055</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2011</study_first_submitted>
  <study_first_submitted_qc>October 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2011</study_first_posted>
  <results_first_submitted>June 19, 2014</results_first_submitted>
  <results_first_submitted_qc>March 12, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 25, 2015</results_first_posted>
  <last_update_submitted>November 15, 2016</last_update_submitted>
  <last_update_submitted_qc>November 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LH pulsatility</keyword>
  <keyword>Obesity</keyword>
  <keyword>Reproduction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Cetrorelix</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BMI ≥30 kg/m2</title>
          <description>BMI ≥30 kg/m2
History of regular menstrual cycles every 25-40 days
Letrozole, Gonadorelin-GnRH, Luveris-lutropin, cetrorelix: Reproductive Hormonal Alterations in Obesity, Aims #1 and 2&quot; Description: comparative study of pathophysiology</description>
        </group>
        <group group_id="P2">
          <title>BMI 18-25 kg/m2</title>
          <description>BMI 18-25 kg/m2
History of regular menstrual cycles every 25-35 days
Letrozole, Gonadorelin-GnRH, Luveris-lutropin, cetrorelix: Reproductive Hormonal Alterations in Obesity, Aims #1 and 2&quot; Description: comparative study of pathophysiology</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BMI ≥30 kg/m2</title>
          <description>BMI ≥30 kg/m2
History of regular menstrual cycles every 25-40 days
Letrozole, Gonadorelin-GnRH, Luveris-lutropin, cetrorelix: Reproductive Hormonal Alterations in Obesity, Aims #1 and 2&quot; Description: comparative study of pathophysiology</description>
        </group>
        <group group_id="B2">
          <title>BMI 18-25 kg/m2</title>
          <description>BMI 18-25 kg/m2
History of regular menstrual cycles every 25-35 days
Letrozole, Gonadorelin-GnRH, Luveris-lutropin, cetrorelix: Reproductive Hormonal Alterations in Obesity, Aims #1 and 2&quot; Description: comparative study of pathophysiology</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in Luteinizing Hormone (LH) Pulse Amplitude (Aim 1)</title>
        <description>Luteinizing Hormone (LH) Pulse Amplitude was measured hourly during the 12 hour study visit, and was compared between the obese and normal weight groups.</description>
        <time_frame>Measured hourly and averaged over the 12 hour study visit</time_frame>
        <population>This study was divided into two aims, and 10 obese and 10 normal weight women completed the study procedures and contributed data for analyses related to Aim 1.</population>
        <group_list>
          <group group_id="O1">
            <title>BMI ≥30 kg/m2</title>
            <description>BMI ≥30 kg/m2
History of regular menstrual cycles every 25-40 days
Letrozole, Gonadorelin-GnRH, Luveris-lutropin, cetrorelix: Reproductive Hormonal Alterations in Obesity, Aims #1 and 2&quot; Description: comparative study of pathophysiology</description>
          </group>
          <group group_id="O2">
            <title>BMI 18-25 kg/m2</title>
            <description>BMI 18-25 kg/m2
History of regular menstrual cycles every 25-35 days
Letrozole, Gonadorelin-GnRH, Luveris-lutropin, cetrorelix: Reproductive Hormonal Alterations in Obesity, Aims #1 and 2&quot; Description: comparative study of pathophysiology</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Luteinizing Hormone (LH) Pulse Amplitude (Aim 1)</title>
          <description>Luteinizing Hormone (LH) Pulse Amplitude was measured hourly during the 12 hour study visit, and was compared between the obese and normal weight groups.</description>
          <population>This study was divided into two aims, and 10 obese and 10 normal weight women completed the study procedures and contributed data for analyses related to Aim 1.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="2.9" upper_limit="5.2"/>
                    <measurement group_id="O2" value="3.6" lower_limit="2.7" upper_limit="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Luteinizing Hormone (LH) Pulse Amplitude (Aim 2)</title>
        <description>Luteinizing Hormone (LH) Pulse Amplitude was measured hourly during the 12 hour study visit, and was compared between the obese and normal weight groups.</description>
        <time_frame>Measured hourly and averaged over the 12 hour study visit</time_frame>
        <population>This study was divided into two aims, and only 12 obese and 11 normal weight women completed the study procedures for Aim 2 that allowed measure of LH pulse amplitude.</population>
        <group_list>
          <group group_id="O1">
            <title>BMI ≥30 kg/m2</title>
            <description>BMI ≥30 kg/m2
History of regular menstrual cycles every 25-40 days
GnRH or gonadorelin (Lutrepulse) and Letrozole were administered in Aim 2. Description: comparative study of pathophysiology</description>
          </group>
          <group group_id="O2">
            <title>BMI 18-25 kg/m2</title>
            <description>BMI 18-25 kg/m2
History of regular menstrual cycles every 25-35 days
GnRH or gonadorelin (Lutrepulse) and Letrozole were administered in Aim 2. Description: comparative study of pathophysiology</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Luteinizing Hormone (LH) Pulse Amplitude (Aim 2)</title>
          <description>Luteinizing Hormone (LH) Pulse Amplitude was measured hourly during the 12 hour study visit, and was compared between the obese and normal weight groups.</description>
          <population>This study was divided into two aims, and only 12 obese and 11 normal weight women completed the study procedures for Aim 2 that allowed measure of LH pulse amplitude.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.21" spread=".32"/>
                    <measurement group_id="O2" value="4.44" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Pregnanediol Glucuronide (PdG) (Aim 2)</title>
        <description>Pregnanediol glucuronide (PdG) was collected daily over the course of one menstrual cycle and averaged.</description>
        <time_frame>Averaged over the length of menstrual cycle</time_frame>
        <population>This study was divided into two aims, and only 12 obese and 10 normal weight women completed the urine collection study procedures for Aim 2 that allowed measure of PdG.</population>
        <group_list>
          <group group_id="O1">
            <title>BMI ≥30 kg/m2</title>
            <description>BMI ≥30 kg/m2
History of regular menstrual cycles every 25-40 days
GnRH or gonadorelin (Lutrepulse) and Letrozole were administered in Aim 2. Description: comparative study of pathophysiology</description>
          </group>
          <group group_id="O2">
            <title>BMI 18-25 kg/m2</title>
            <description>BMI 18-25 kg/m2
History of regular menstrual cycles every 25-35 days
GnRH or gonadorelin (Lutrepulse) and Letrozole were administered in Aim 2. Description: comparative study of pathophysiology</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Pregnanediol Glucuronide (PdG) (Aim 2)</title>
          <description>Pregnanediol glucuronide (PdG) was collected daily over the course of one menstrual cycle and averaged.</description>
          <population>This study was divided into two aims, and only 12 obese and 10 normal weight women completed the urine collection study procedures for Aim 2 that allowed measure of PdG.</population>
          <units>ug/cycle</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.1" spread="33"/>
                    <measurement group_id="O2" value="88.7" spread="64.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Follicle Stimulating Hormone (FSH) (Aim 1)</title>
        <description>Follicle-stimulating hormone was measured hourly during the 12 hour study visit, and was compared between the obese and normal weight groups.</description>
        <time_frame>Measured hourly and averaged over the 12 hour study visit</time_frame>
        <population>This study was divided into two aims, and only 10 obese and 10 normal weight women completed the study procedures for Aim 1 that allowed measure of FSH.</population>
        <group_list>
          <group group_id="O1">
            <title>BMI ≥30 kg/m2</title>
            <description>BMI ≥30 kg/m2
History of regular menstrual cycles every 25-40 days
Letrozole, Gonadorelin-GnRH, Luveris-lutropin, cetrorelix: Reproductive Hormonal Alterations in Obesity, Aims #1 and 2&quot; Description: comparative study of pathophysiology</description>
          </group>
          <group group_id="O2">
            <title>BMI 18-25 kg/m2</title>
            <description>BMI 18-25 kg/m2
History of regular menstrual cycles every 25-35 days
Letrozole, Gonadorelin-GnRH, Luveris-lutropin, cetrorelix: Reproductive Hormonal Alterations in Obesity, Aims #1 and 2&quot; Description: comparative study of pathophysiology</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Follicle Stimulating Hormone (FSH) (Aim 1)</title>
          <description>Follicle-stimulating hormone was measured hourly during the 12 hour study visit, and was compared between the obese and normal weight groups.</description>
          <population>This study was divided into two aims, and only 10 obese and 10 normal weight women completed the study procedures for Aim 1 that allowed measure of FSH.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="2.1" upper_limit="4.2"/>
                    <measurement group_id="O2" value="3.3" lower_limit="3" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Follicle Stimulating Hormone (FSH) (Aim 2)</title>
        <description>Follicle-stimulating hormone was measured hourly during the 12 hour study visit, and was compared between the obese and normal weight groups.</description>
        <time_frame>Measured hourly and averaged over the 12 hour study visit</time_frame>
        <population>This study was divided into two aims, and only 12 obese and 11 normal weight women completed the study procedures for Aim 2 that allowed measure of FSH.</population>
        <group_list>
          <group group_id="O1">
            <title>BMI ≥30 kg/m2</title>
            <description>BMI ≥30 kg/m2
History of regular menstrual cycles every 25-40 days
GnRH or gonadorelin (Lutrepulse) and Letrozole were administered in Aim 2. Description: comparative study of pathophysiology</description>
          </group>
          <group group_id="O2">
            <title>BMI 18-25 kg/m2</title>
            <description>BMI 18-25 kg/m2
History of regular menstrual cycles every 25-35 days
GnRH or gonadorelin (Lutrepulse) and Letrozole were administered in Aim 2. Description: comparative study of pathophysiology</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Follicle Stimulating Hormone (FSH) (Aim 2)</title>
          <description>Follicle-stimulating hormone was measured hourly during the 12 hour study visit, and was compared between the obese and normal weight groups.</description>
          <population>This study was divided into two aims, and only 12 obese and 11 normal weight women completed the study procedures for Aim 2 that allowed measure of FSH.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.31" spread=".38"/>
                    <measurement group_id="O2" value="6.18" spread=".94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>BMI ≥30 kg/m2</title>
          <description>BMI ≥30 kg/m2
History of regular menstrual cycles every 25-40 days
Letrozole, Gonadorelin-GnRH, Luveris-lutropin, cetrorelix: Reproductive Hormonal Alterations in Obesity, Aims #1 and 2&quot; Description: comparative study of pathophysiology</description>
        </group>
        <group group_id="E2">
          <title>BMI 18-25 kg/m2</title>
          <description>BMI 18-25 kg/m2
History of regular menstrual cycles every 25-35 days
Letrozole, Gonadorelin-GnRH, Luveris-lutropin, cetrorelix: Reproductive Hormonal Alterations in Obesity, Aims #1 and 2&quot; Description: comparative study of pathophysiology</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research Regulatory Manager</name_or_title>
      <organization>University of Colorado Denver</organization>
      <phone>303-724-6501</phone>
      <email>Chanel.mansfield@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

